Colon Cancer Treatment Costs for Medicare and Dually Eligible Beneficiaries
Colon Cancer Treatment Costs for Medicare and Dually Eligible Beneficiaries
复制标题
DOI：
--
复制
发表时间：
2009-09
影响因子：
--
通讯作者：
Zhehui Luo;C. Bradley;B. Dahman;J. Gardiner
中科院分区：
文献类型：
--
作者：
Zhehui Luo;C. Bradley;B. Dahman;J. Gardiner
为了根据癌症分期、合并症、治疗方案和医疗补助资格来估计诊断后 1 年结肠癌治疗的费用，我们从密歇根肿瘤登记处提取了 1997 年至 2000 年间诊断的 66 岁及以上结肠癌患者的起始队列，并将患者与医疗保险分母文件中的非癌症对照受试者进行匹配。我们使用差异-无差异法来估计癌症引起的成本，并在诊断前控制成本。每个 Medicare 患者的平均结肠癌总费用为 29,196 美元。该方法可应用于纵向数据，以从肿瘤登记处识别出事件患者的一开始就估计癌症的长期成本。
To estimate the cost attributable to colon cancer treatment 1 year after diagnosis by cancer stage, comorbidity, treatment regimen, and Medicaid eligibility, we extracted an inception cohort of colon cancer patients aged 66 and older diagnosed between 1997 and 2000 from the Michigan Tumor Registry Patients were matched to non-cancer control subjects in the Medicare Denominator file. We used the difference-indifferences method to estimate costs attributable to cancer, controlling for costs prior to diagnosis. The mean total colon cancer cost per Medicare patient was $29,196. The method can be applied to longitudinal data to estimate long term costs of cancer from inception where incident patients are identified from a tumor registry.